Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy

Azin Aghamajidi¹, Pooya Farhangnia¹, Salar Pashangzadeh², Amirmasoud Rayati Damavandi³⁴ and Reza Jafari⁵*

Abstract
Oncoviruses, known as cancer-causing viruses, are typically involved in cancer progression by inhibiting tumor suppressor pathways and uncontrolled cell division. Myeloid cells are the most frequent populations recruited to the tumor microenvironment (TME) and play a critical role in cancer development and metastasis of malignant tumors. Tumor-infiltrating myeloid cells, including tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), tumor-associated dendritic cells (TADCs), and tumor-associated neutrophils (TANs) exert different states from anti-tumorigenic to pro-tumorigenic phenotypes in TME. Although their role in the anti-tumorigenic state is well introduced, their opposing roles, pro-tumorigenic activities, such as anti-inflammatory cytokine and reactive oxygen species (ROS) production, should not be ignored since they result in inflammation, tumor progression, angiogenesis, and evasion. Since the blockade of these cells had promising results against cancer progression, their inhibition might be helpful in various cancer immunotherapies. This review highlights the promoting role of tumor-associated myeloid cells (TAMCs) in the pathophysiology of human virus tumorigenesis.

Keywords Myeloid cells, Oncoviruses, Tumor microenvironment, Cancer progression, Immunotherapy

Background
Human oncogenic viruses, known as oncoviruses, potentially contribute to an estimated 12–20% of human cancers, accounting for a large fraction of the global cancer burden [1]. Recently, several oncoviruses with DNA or RNA genomes such as human papillomavirus (HPV), Epstein-Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), human herpesvirus-8 (HHV-8), human T-cell lymphotropic virus-1 (HTLV-1), and Merkel cell polyomavirus (MCV) have been recognized as the primary contributors to cancer development [2]. Viral carcinogenesis is a complex process associated with viral factors and immune escape mechanisms. There is interesting crosstalk between different viral and host factors which mediate the signaling pathways and cellular process. In general, oncoviruses can inhibit the tumor suppressor pathway p53, which supports primary
tumor growth and progression [3]. It has also been demonstrated that viral factors potentially activate PI3K-Akt-mTOR, Notch, and Wnt pathways leading to cell overgrowth, tumor invasion, and angiogenesis [4]. On the other hand, oncoviruses establish an infection-associated chronic inflammation that could mediate cancer development through different mechanisms including tissue remodeling, angiogenesis, and production of growth factors [5]. The tumor microenvironment (TME) consists of different immune cells which play a prominent role in the tumor progression. Myeloid cells are the heterogeneous population of the innate immune system, which is considered the first line of defense. These cells include tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), tumor-associated dendritic cells (TADCs), and tumor-associated neutrophils (TANs) that predominantly infiltrate the TME [6]. Despite the central role of myeloid cells in regulating anti-tumor immune responses, tumor-associated myeloid cells (TAMCs) can promote tumorigenesis mechanisms [7]. It is noteworthy that TAMCs exert crucial pro-tumorigenic functions in regulating cancer-related inflammation, expression of pro-angiogenic factors, tumor angiogenesis, tumor progression, and promotion of immune evasion [8]. The pro-tumorigenic functions of TAMCs, including anti-inflammatory cytokine secretion and chronic ROS production, have been considered significant obstacles to developing effective cancer treatments. Therefore, TAMCs are considered a double-edged sword of immune effectors in cancer progression. Given the dual role of TAMCs in cancer development and their therapeutic potential, this review highlights the role of tumor-promoting myeloid cells in the pathogenesis of human oncoviruses and provides new insights into cancer immunotherapy.

**Anti- and pro-tumorigenic function of myeloid cells in cancer pathogenesis**

Myeloid cells exert an immunosuppressive activity to combat the proliferating tumor cells; however, it has been demonstrated that they represent opposing functions from anti-tumorigenic to pro-tumorigenic phenotypes in the TME. Hence, we briefly describe the mechanism of the anti- and pro-tumorigenic function of TAMCs in the immune escape and cancer pathogenesis.

**Tumor-associated regulatory dendritic cells (TAR-DCs)**

Dendritic cells (DCs) are a double-edged sword population in the TME. Plasmacytoid (pDC), conventional (cDC1 or cDC2), and inflammatory DC (moDC) are three phenotypically and functionally distinct subsets of DCs [9]. These immune cells play a crucial role in various cancer types, including breast, lung, colorectal, ovarian, head and neck, bladder, gastric, and renal cancer [10]. Although, DCs mediate antigen trafficking and stimulation of CD8+ T-cell responses, however, TAR-DCs exhibited immunosuppressive properties by low expression of costimulatory molecules and high expression of regulatory molecules. Stromal-cell derived factor-1 (SDF-1) which is also known as CXCL12, in the TME of malignant tumors and high expression of CXCL4 ligand results in the accumulation of DCs in TME. Immunoglobulin-like transcript 7 (ILT7) recognizes bone marrow stromal cell antigen 2 (BST2), which is highly expressed on tumor cells, resulting in negative regulation of the interferon responses [11]. It has been demonstrated that IL-10 produced by TAMs potentially suppresses the secretion of IL-12, which mediates immune escape and metastatic progression. The inhibition of IL-10 could restore the functionality and cytokine production of DCs [12].

**Tumor-associated macrophages (TAMs)**

Tumor-associated macrophages (TAMs) are abundant myeloid cells in the TME with anti-tumorigenic or strongly pro-tumorigenic phenotypes. Macrophage colony-stimulating factor (M-CSF) is highly expressed in the TME, which recruits the macrophages from the bone marrow or spleen [13]. TAMs are classified as classically activated-M1 and alternatively activated-M2 macrophages which induce anti-tumorigenic Th1 immune responses and pro-tumorigenic functions such as tumor growth and invasion, immune suppression, and angiogenesis which is mediated by cytokine and chemokine production respectively [14]. M1 macrophages exert anti-tumor activity by direct cytotoxic effects mediated by ROS production, and antibody-dependent cell-mediated cytotoxicity (ADCC) to eliminate tumor cells [15]. M2 macrophages are predominantly the vast majority of non-malignant TAMs associated with the production of immunosuppressive chemokines and factors including TGF-β and IL-10. Furthermore, TAMs are related to angiogenesis by producing pro-angiogenic factors, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and matrix metalloproteinase (MMP) [13]. TAM can enhance tumor proliferation and invasion mediated by activation of NF-κB and STAT3 and expression of pro-inflammatory cytokines [16]. Elevated levels of TAMs are correlated with poor prognosis of diverse types of cancers [17, 18].

**Myeloid-derived suppressor cells (MDSCs)**

MDSCs are developmentally immature non-macrophage cells with an immunosuppressive function. These cells potentially prevent the activation of CD4+ and CD8+ T-cells. Also, it has been suggested that MDSCs suppress NK cells, which may disturb anti-tumor immunity [19]. Therefore, MDSCs are considered a serious hurdle
Increased M2 macrophages

Inhibition of p53,
Activation of TLR2/PI3K/AKT/STAT3

Upregulation of IL-1, IL-6, and GM-CSF
MDSC proliferation
Increased M2 macrophages
Inhibition of NK cell and T-cell senescence

Activation of NKG2D in NK cells
T cell senescence

MDSC proliferation
Downregulation of IFN-γ

Tumor-promoting myeloid cells and human oncoviral infection
Here we highlight the mechanistic strategies by oncoviral infection in immune disturbances (Table 1).

Epstein-Barr virus (EBV)

First identified in the tumor cells of Burkitt lymphoma, is now associated with a strikingly diverse variety of lymphoproliferative lesions and malignant lymphomas of B, T, and NK cell origin [27]. Here, we highlight the association between EBV and tumor-promoting myeloid cells such as MDSCs and TAMs.

MDSCs
The latent membrane protein-1 (LMP1) is the primary oncogene of EBV that plays a critical role in the MDSCs proliferation and tumor immunosuppression. A large fraction of MDSCs is found in patients with EBV-associated T/NK cell lymphoproliferative diseases, which may dampen the antiviral T-cell responses [28]. LMP1-mediated glycolysis enhances the production of IL-1β, IL-6, and GM-CSF, the proliferation of tumor-associated MDSCs, and the inhibition of T-cells and NK cells, which lead to tumor immunosuppression [29, 30]. The accumulation of PMN-MDSCs in nasopharyngeal cancer survivors with persistent hepatitis B may suppress the host immune response [31] to the Epstein-Barr virus and be linked to tumor recurrence via ER stress/ROS pathway.

TAMs
In gastric cancer, the EBV-encoded miR-BART11 targets FOXP1 to enhance the tumor-associated macrophage-induced epithelial-mesenchymal transition [32]. Zhang et al. revealed that in nasopharyngeal carcinoma (NPC) cells, EBV induced M2 phenotype in TAMs and elevated the p-ATR expression. These two inductions were highly connected and linked to higher tumor staging, lymph node metastases, and poor patient prognosis [33]. Activation of ATR triggered by EBV increased subcutaneous tumor development, elevated Ki67 production, and lung metastasis in nude mice through the M2-type TAMs recruitment [33]. CD68 as a TAMs marker was higher in EBV-positive NPC. However, between EBV-positive and EBV-negative NPC, there was no variation in M2 macrophage number [34]. The survival of EBV+ tumor cells is dependent on TAMs in the EBV-positive TME [35]. The EBV status of lymphoma cells affected TAMs by up-regulation of CXCR10 and VEGF, causing angiogenesis and
tumor survival. The in vivo reduction of macrophages revealed that they are required to survive EBV-positive tumor cells [35].

EBV expression has been identified in lesional macrophages of different cancers, ranging from thyroid to uterine carcinoma and some types of lymphoma that possibly elicit EBV lytic infection of macrophages in many tumor-associated macrophages in EBV-related malignancies [36].

In classical Hodgkin's lymphoma, tumor-infiltrating macrophages are linked to a poor prognosis and the presence of EBV [37]. Increasing the number of TAMs is related to a reduction in overall survival, while greater levels of markers are statistically substantially associated with the presence of EBV infection [38].

**Hepatitis B virus (HBV)**
The most frequent kind of liver cancer is hepatocellular carcinoma (HCC). HBV is a chronic infection that affects over 350 million individuals worldwide. At least half of all HCC cases globally are caused by chronic hepatitis B virus (HBV) infection [39]. Here, we highlight evidence of the association between HBV and tumor-promoting myeloid cells.

**MDSCs**
HCC patients had considerably greater percentages of MDSCs and PMN-MDSCs than chronic hepatitis B patients and healthy controls [40]. Pal et al. have demonstrated that the induction of regulatory T-cells (Tregs) by myeloid-derived suppressor cells in persistent HBV infections featuring high viral surface antigen is long-lasting and persists following antiviral treatment [41]. In the chronic liver failure posed by HBV, the proliferation of myeloid-derived suppressor cells was strongly associated with the severity and course of the disease [42].

**Macrophages**
Macrophages are monocytic phagocytes with antigen-presentation and cytokine-producing capabilities. The tissue-specific liver macrophages are Kupffer cells dominating other innate immune cells in the organ [43]. From the onset of HBV infection through the beginning and development of HCC, macrophages act as the key mediator of the pathogenic process. Kupffer cells have a role in inflammatory responses and tolerance generation in the early stages of infection [44]. In a specifically modified murine model of HBV infection, liver dysfunction was linked to an enormous frequency of human M2 macrophages [45]. Kupffer cells may impede the progression of HBV-associated HCC by inhibiting T-cell-mediated anti-tumor activity, limiting T-cell activation with PD-L1 expression on monocytes, and causing Tim3+/CD4+ and Tim3+/CD8+ cells to senescence [46, 47].

**NK cells**
The lymphocytes in the human liver tissue are predominantly natural killer cells (NK cells). Patients with persistent HBV and HCV infection have more NK cells in their liver [44]. A ligand of the NKG2D receptor, MICA, is upregulated in HBV infection, and soluble MICA levels have been linked to modulating responses directed by NK cells, which are essential in developing HCC in HBV-associated HCC patients [44, 48]. Several mechanisms have been shown to selectively impair NK cell function after chronic HBV infection. These include TGF-β and IL-10 stimulation of NK cells and their increased expression of Tim-3 triggered by HBV, hindering their activity [49, 50].

**Hepatitis C virus (HCV)**
HCV infection affects more than 270 million individuals globally. HCV produces a chronic and lifelong infection in most infected individuals. This persistent inflammation in the liver leads to macronodular cirrhosis in 20% of people who contract it. A 4 to 7% yearly risk of progressing to HCC is associated with these individuals [51].

Through the TLR2/Pi3K/AKT/STAT3 signaling cascade, HCV induced MDSC-like suppressive monocytes that activated CD4+Foxp3+ Tregs and inhibited the autologous CD4+ T-cell activation [52]. HCV stimulates the accumulation of CD33+ MDSCs, which reduces T-cell responsiveness via the production of ROS [53]. IFN-γ production by natural killer cells is suppressed by MDSCs induced by HCV, which alter cellular metabolism by inhibiting arginase-1 [54]. MDSCs triggered by HCV promote the development of Tregs while inhibiting the activity of effector T-cells [55]. Hepatitis C core protein polarizes granulocytic myeloid-derived suppressor cells via the IL-10/STAT3 signaling [56].

A long non-coding RNA (lncRNA) named HOXA transcript antisense RNA myeloid-specific 1 (HOTAIRM1) targets HOXA1 gene expression to regulate myeloid cell development. HOTAIRM1 enhances MDSCs growth and suppressive activities during HCV infection through the HOXA1-miR124 axis [57]. Exosomes associated with HCV suppress miR-124, which promotes the growth of myeloid-derived suppressor cells [58]. RUNX1 overlapping RNA (RUNXOR) is another lncRNA that targets runt-related transcription factor 1 (RUNX1) and is crucial for myeloid cell development. Exosomes associated with HCV through the STAT3-miR124 axis upregulate RUNXOR and RUNX1, increasing the MDSCs population and suppressive capabilities [59].

**Human herpesvirus 8 (HHV-8)**
The causative agent of Kaposi’s sarcoma (KS) is Kaposi’s sarcoma herpesvirus (KSHV; also known as human herpesvirus 8 (HHV-8)). KS is the most prevalent neoplasm
among untreated HIV patients, although it may also happen in immunosuppressive conditions after organ transplantation [60]. KSHV vFLIP is a latent infection-associated viral oncoprotein. CD11b+Gr1+ cells with suppressor immune phenotype are induced by vFLIP, which remodels myeloid differentiation and causes their proliferation [61]. Based on the evidence, DC exerts decreased antiviral immune responses and altered cytokine production during the HHV-8 infection [62]. It has also been demonstrated that HHV-8 infection is associated with prostate cancer [63]. Moreover, the study on the Iranian population has indicated the high prevalent rate of the HHV-8 genome among patients with cervical cancer [64]. Therefore, it can be perceived that HHV-8 infection may be associated with an increased risk of cervical cancer.

**Human papillomavirus (HPV)**

Cervical cancer is caused by certain HPV (human papillomavirus) genotypes. Other anogenital cancers and a subset of head and neck cancers seem to be caused by the same genotypes. It is necessary to sustain the malignant development of cervical cancer cells by inducing the expression of particular viral oncoproteins, E6 and E7, which specifically inhibit the tumor suppressors p53 and RB [65]. In malignancies pertaining to HPV, MDSCs are related to both poor clinical outcomes and resistance to treatment. They inhibit the activity of CTLs, down-regulate IFN-γ, and increase the frequency of Tregs, all of which contribute to carcinogenesis. Furthermore, compared to normal controls, their levels were elevated, indicating a clear relationship between pathological grade and their levels [66–68]. Activating CD8+ effector memory T-cells and controlling MDSCs together allowed protection against cancers caused by the HPV-16 serotype [69].

The oncogenic mechanisms of tumor-promoting myeloid cells in reviewed human oncoviral infections have been depicted in Fig. 1.

**Tumor-promoting myeloid cells and potential targets for immunotherapy of human oncoviruses**

Due to the immunosuppressive nature of MDSCs and TAMs, these cells have been considered two main potential targets for cancer immunotherapy. Although, different therapeutic approaches to target these immunosuppressive myeloid cells are being investigated. Here, we
will provide the strategies for repolarization and revival of tumor-promoting myeloid cells (Table 2).

**Blocking recruitment**

Blocking the recruitment of MDSCs and TAMs may be a beneficial strategy for reducing tumorigenesis and immunosuppression. CCR2+ TAMs and MDSCs in TME are recruited by the CCL2 chemokine [70–72]. Blocking CCL2/CCR2 axis reverses MDSCs infiltration into the tumor, augmenting the effectiveness of the cancer immunotherapy [73]. In breast cancer models, removing CCR2 blockade induces tumor progression, migration, and angiogenesis [74]. Clinical studies are now underway for anti-CCR2 agents, including carlumab (CNTO 888), PF-04136309, MLN1202, BMS-813,160, and CCX872-B [75, 76].

The CXCL12/CXCR4 axis governs TAMs’ migration into hypoxic tumor areas through the endothelial barrier [77]. Targeting the CXCL12/CXCR4 axis in multiple cancer models, including prostate and breast cancer, reduces tumor burden and metastatic susceptibility by preventing TAM infiltration [78, 79].

**Depleting macrophage populations in the TME**

TAMs are among the most common and important non-neoplastic cell groups in the established TME. The differentiation of macrophages into tumor-suppressive M1 or tumor-promoting M2 types is an important stage in the formation of the TME. Implementing three strategies through this pivotal axis could pave for novel cancer treatment strategies. These strategies could alter M2 TAM survival and apoptotic mechanisms or disrupt their signaling pathways, suppress chemotactic potential toward the tumor, and reprogram M2 TAMs to produce M1 phenotype macrophages [80].

Bisphosphonates elicit myeloid cell cytotoxicity by preferentially targeting phagocytic cells, including TAMs [81]. Zoledronate, a third-generation bisphosphonate, is cytotoxic to TAMs that express matrix metalloproteinase-9 (MMP9) and improves macrophage anti-tumor activity by polarizing monocytes toward pro-inflammatory phenotype [76, 82]. Trabectedin, a drug mainly used for soft tissue malignancies, inhibits TAMs, enhancing anti-cancer adaptive immunity in response to anti-programmed cell death protein 1 (PD-1) treatment [83]. Trabectedin causes mononuclear phagocytes to undergo accelerated apoptosis. In animal tumor models, trabectedin reduced angiogenesis by selectively depleting monocytes/macrophages in the blood, spleens, and tumors [84].

**Reprogramming metabolism**

Several agents, including growth factors, could modify macrophages’ immune and metabolic responses in their residing microenvironment. This mechanism is reflected in the tricarboxylic acid (TCA) cycle disruption in M1 macrophages with the stimulation of inflammatory mediators resulting in IL-1 and Fatty acid synthesis and switching to pro-inflammatory phenotype [76, 85–88]. M2 macrophages, on the other hand, have an intact TCA cycle by external anti-inflammatory stimulation, which promotes mitochondrial oxidative phosphorylation (OXPHOS), yielding a higher ATP production [76, 89]. Inhibiting ATP production in M2 macrophages with an ATP synthase or a hexokinase inhibitor decreases anti-inflammatory characteristics and suppresses pro-tumorigenic function [90, 91].

### Table 2 The strategies of repolarization and revival of tumor-promoting myeloid cells

| Mechanism                  | Molecular and/or Cellular Target | Agent(s) | Reference |
|----------------------------|---------------------------------|----------|-----------|
| Blocking recruitment       | CXCR4/CCR12 axis                | AMD3100  | [125]     |
|                            | PI3K                            | IPI-549  | [126]     |
|                            | mTORC                           | Rapalogs | [127]     |
|                            | BTK                             | Ibrutinib| [128]     |
|                            | CCR2/CCL2                       | Carlumab, C1142, Bindarit | [129-132] |
| Inhibiting differentiation | CSF1R/CSF1 axis                 | Enactuzumab (RG7155), Cabralizumab (FPAA008), Pexidartinib, ARRY-382, SNFX-6352, BL2945, AMG820, IMC-C54, LY3022855 | [93-140] |
| CD40 activation            | CD40                            | Selicreumab, APX005M, SEA-CD40, CP-870-893 | [141-144] |
| TLR activation             | TLR1                            | Pam3     | [145]     |
|                            | TLR2                            | Pam3-CSK4, SMU-Z1, LTA | [145]     |
|                            | TLR3                            | Poly IC  | [148]     |
|                            | TLR4                            | GS1K795091| [149]     |
|                            | TLR6                            | LTA      | [150]     |
|                            | TLR7/8                          | NKTR262, Resiquimod, Imiquimod, SM-052 | [151-153] |
|                            | TLR9                            | IMO-2125, CMP-001, SD-101 CpG | [154-156] |
| Immune checkpoint blockade  | SIRPa/CD47 axis                 | CV1, TTI-621, HuSF9-G4 | [157-159] |
| PI3K inhibition            | PI3K                            | SF1126, SXR3207, Clotrizamole | [111-113] |
| HDAC inhibition            | HDAC                            | TMP195   | [116]     |
| Angiogenesis inhibition    | VEGF/VEGFR axis                 | mAb      | [161]     |
| Apoptosis                  | TAM                             | Zoledronate, Trabectedin | [82, 84] |
| Inhibition of ATP synthesis | ATP synthase                    | Oligomycin, 2-Deoxyglucose | [162, 163] |
Reprogramming cellular signaling

To induce tumoricidal potential in MDSCs and TAMs, several factors could be used to reprogram their signaling pathways, including colony-stimulating factor 1/colony-stimulating factor 1 receptor (CSF1R) blockade, TLR agonists, PI3K inhibitors, CD40 agonists [64], and Class IIa histone deacetylase inhibitors (HDACis) [76, 92, 93]. Promising targets are the macrophage surface receptors that aid antibody-dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP). Macrophages harbor a membrane protein called signal regulatory protein alpha (SIRP-α) binding to CD47 molecules expressed on tumoral cells, which help them evade tumor immunosurveillance [94]. However, anti-SIRPa antibodies cause tumor cell phagocytosis while preserving T-cells [95].

TLRs agonists could induce pro-inflammatory and anti-tumor phenotypes in TAMs. Feng et al. developed a glucosamannan polysaccharide with acetyl modification to the degree of 1.8 (acGM-1.8), which stimulates TLR2 signaling and promotes macrophages toward becoming anti-tumor [96]. TLR7/8 agonist-loaded nanoparticles augment cancer immunotherapy via polarizing TAMs [97]. TLR-3 stimulation via modulating IFN-αβ signaling restricts tumor progression by skewing M2 macrophages to the M1 phenotype [98]. TLR 7/8 agonists also stimulate human MDSCs to differentiate toward anti-tumor M1-like macrophages, which may reverse the suppressive action of MDSCs [99].

CSF1/CSF1R blockade in pancreatic cancer models could enhance immune checkpoint T-cell therapy outcomes while reprogramming TAMs [100]. Moreover, blocking the CSF1/CSF1R axis reduces mesothelioma growth and improves anti-PDL1 immunotherapy efficacy [101], and CSF1R inhibition minimizes the development of cervical and mammary tumors in mice by lowering TAMs turnover and increasing the CD8+ T-cell infiltration [102]. Inappropriate response to immunotherapy in indoleamine 2,3-dioxygenase-expressing malignancies may be overcome by targeting MDSCs with CSF1R inhibition [103]. Pro-tumorigenic TAMs are reduced, and pro-tumorigenic PMN-MDSCs are recruited when CSF1R is inhibited [104]. Indeed, CSF1R suppression enabled tumor-infiltrating PMN-MDSCs to be recruited by carcinoma-associated fibroblasts. Thus, CXCR2 inhibitors may augment the anti-cancer effects of CSF1R inhibition by preventing PMN-MDSCs recruitment [104].

TAMs are sensitive to profound and abrupt reprogramming in the presence of a CD40 agonist when CSF-1R signaling is inhibited. Despite the short window of macrophage hyperactivation, simultaneous CSF-1R inhibition plus CD40 stimulation is adequate to establish a pro-inflammatory TME that revives an efficient immune response for T-cell immune checkpoint therapy [105]. Likewise, CD40 agonist, combined with CSF-1R, blockades reconditions TAMs and promotes potent anti-tumor immunity [106]. Activated macrophages with CD40 agonist invaded tumors immediately, were tumoricidal, and aided tumor stroma elimination [107]. In a pancreatic cancer mouse model, dendritic cell vaccination and CD40-agonist combined treatment enable T-cell-dependent anti-tumor immunotherapy [108].

A first in vivo evidence revealed that pharmacological suppression of the PI3K p110δ subunit inhibits the growth of breast cancer by specifically targeting cancer cells and macrophages [109]. Li et al. indicated that TAM accumulation in the glioblastoma microenvironment is suppressed by PI3K inhibition, which results in an extraordinary temozolomide response [110]. A pan-PI3K inhibitor (SF1126) reduced VEGF and other proangiogenic factors released by macrophages, blocking tumor-induced angiogenesis [111]. Joshi et al. demonstrated anti-tumor immunity by macrophage Syk-PI3Kγ axis [112]. Additionally, tumor immunosuppression is relieved by SRX3207, a novel dual Syk-PI3K inhibitor [112]. Clostrimazole has anti-cancer characteristics in a mice melanoma model, functioning as a PI3K inhibitor and causing TAMs to repolarize [113].

HDAC inhibition with trichostatin-A increases anti-PD-L1-mediated tumor suppression and potentiates macrophage anti-tumor activity [114]. TMP195, an HDAC Class IIa inhibitor, may transform tumor-infiltrating monocytes and macrophages into cells able to sustain a robust CD8+ T-cell-mediated anti-tumor immune response in breast cancer and reduce metastasis [115, 116].

Immune checkpoint blockade (ICB)

The PD-1 and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) immune checkpoints are predominantly produced by effector immune cells, including T and NK cells. Targeting these molecules have exciting therapeutic potential by affecting myeloid biology [117, 118]. Because PD-L1 is expressed on MDSCs and TAMs, ICB using anti-PD-L1 may directly impact myeloid cell activities in TME [119]. There is a difference in response to PD-1 and PD-L1 inhibition in myeloid cells, with the latter leading to more potent immune responses by activating inflammasomes and expressing IL-18 [120]. The protective immune response to tumor cells requires inflammasome activation [121].

CD47/SIRPa axis has been identified as a critical macrophage immune checkpoint. CD47 is a “don’t eat me” signal that is overexpressed in myeloid malignancies and causes tumors to evade macrophage phagocytosis. CD47 blockade causes leukemic cells to be engulfed and therapeutically eliminated [122]. CD47 blockade combined with trastuzumab eradicates...
HER2-positive breast cancer cells while also overcoming trastuzumab resistance [123]. Radioresistant breast cancer cells are eliminated when CD47 and HER2 are blocked [124].

**Conclusion**

According to the clinical and pre-clinical evidence, TAMCs play a dual role in cancer via anti-tumorigenic and pro-tumorigenic effects. TAMCs have pro-tumorigenic and immunosuppressive functions by different mechanisms including TGF-β and IL-10 anti-inflammatory cytokine secretion, ROS production, and mediation of angiogenesis through VEGF and HGF production. Hence, TAMCs could be actively involved in cancer progression, and immune escape results in poor prognosis, adverse clinical outcomes, and a low response rate to cancer treatment. Although diverse cancer-related immunotherapies such as ICBs have been investigated, targeting promoting pathways orchestrated by myeloid cells could shed a light on a new therapeutic approach and may improve cancer immunotherapy. Blocking myeloid cells’ recruitment, macrophage population depletion, reprogramming of metabolism, and cellular signaling might be considered helpful strategies for repolarization and revival of tumor-promoting myeloid cells.

**Abbreviations**

mAb  Monoclonal antibody.
TAM  Tumor-associated macrophage.
TLR  Toll-like receptor.
HDAC  Histone deacetylase.
VEGF  Vascular endothelial growth factor.
CSF1  Colony-stimulating factor 1.
CSF1R  Colony-stimulating factor 1 receptor.
LTA  Lipoteichoic acid.
BTK  Bruton tyrosine kinase.
SIRPα  Signal regulatory protein alpha.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

Conception and manuscript design: R.J. Collection of data: A.A, P.F, S.P, A.R.D. and R.J. Manuscript writing: A.A, P.F, S.P, A.R.D. and R.J. Designing of the figure: A.R.D. Made important revisions and confirmed final revision: R.J. All authors reviewed and approved the final version of the manuscript.

**Funding**

Not applicable.

**Data availability**

Not applicable.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Mui UN, Haley CT, Tyring SK. Viral Oncology: Molecular Biology and Pathogenesis. J Clin Med. 2017;6(12).
2. Guven-Maurov E, Tsai C-I, Nussinov R. Oncoviruses Can Drive Cancer by Rewiring Signaling Pathways Through Interface Mimicry. Frontiers in Oncology. 2019;9.
3. Tomasello ML, Annunziata C, Tomasello AL, Buonaguro L, Buonaguro FM. Human Oncoviruses and p38 Tumor Suppressor Pathway Deregression at the Origin of Human Cancers. Cancers (Basel). 2018;10(7).
4. Dzobo K. The Role of Viruses in Carcinogenesis and Molecular Targeting. From Infection to Being a Component of the Tumor Microenvironment. OMICS. 2021;25(6):358–71.
5. Goldszmid RS, Dzutsev A, Trinchieri G. Host immune response to infection and cancer: unexpected commonalities. Cell Host Microbe. 2014;15(3):295–305.
6. Schoppmeyer R, Zegers S, Martinelli L, Pintado P, Tardio J, Hagemann J. Oncovirus-Infected Human Cells Mediate Tumor Immunity. Immunity. 2019;50(3):533–46.
7. Chen Y, Shen S, Li X, Zhang T. Tumor-Associated Macrophages: Role in Tumorigenesis and Immunotherapy Implications. J Cancer. 2021;12(1):54–64.
8. Hourani T, Holden JA, Li W, Lenzo JC, Hadjigiosl S, O'Brien-Simpson NM. Tumor-Associated Macrophages Origin, Recruitment, Phenotypic Diversity, and Targeting. Frontiers in Oncology. 2021;11.
9. Tran J, Meyer H, et al. Myeloid derived suppressor cells inhibit natural killer cells in the Tumor Microenvironment. Semin Cancer Biol. 2012;22(4):298–306.
10. Aghamajidi A, Tsai C-J, Nussinov R. Oncoviruses Can Drive Cancer by Rewiring Signaling Pathways Through Interface Mimicry. Frontiers in Oncology. 2021;11:583084.
11. Xia Y, Shen S, Verma IM, NF-kB, an active player in human cancers. Cancer Immunol Res. 2014;2(9):823–30.
12. Zhang BC, Gao J, Wang J, Rao ZG, Wang BC, Gao JF. Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med Oncol. 2011;28(4):1447–52.
13. Hu Y, He M-Y, Zhu L-F, Yang C-C, Zhou M-L, Wang Q, et al. Tumor-Associated Macrophages Correlate with the Clinicopathological Features and Poor Outcomes via Inducing Epithelial to Mesenchymal Transition in Oral Squamous Cell Carcinoma. J Experimental Clin Cancer Res. 2021;40(1):12.
14. Jegla F, Sanseverino E, Gabrilovich D. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485–98.
15. Sica A, Porta C, Morlacchi S, Banfi S, Strauss L, Rimoldi M, et al. Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs). Cancer Microenvir. 2012;5(2):133–49.
16. Guven-Maurov E, Tsai C-I, Nussinov R. Oncoviruses Can Drive Cancer by Rewiring Signaling Pathways Through Interface Mimicry. Frontiers in Oncology. 2021;11:583084.
17. Hu Y, He M-Y, Zhu L-F, Yang C-C, Zhou M-L, Wang Q, et al. Tumor-Associated Macrophages Correlate with the Clinicopathological Features and Poor Outcomes via Inducing Epithelial to Mesenchymal Transition in Oral Squamous Cell Carcinoma. J Experimental Clin Cancer Res. 2021;40(1):12.
18. Jegla F, Sanseverino E, Gabrilovich D. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485–98.
19. Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019;121(1):16–25.
20. Hoescht B, Vogtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the Nkp30 receptor. Hepatology. 2009;50(3):799–807.
21. Ohl K, Tenbrock K. Reactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression. Front Immunol. 2018;9:2499.
22. Masucci MT, Minopoli M, Carriero MV. Tumor Associated Neutrophils: Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy. Front Oncol. 2019;9:1146.
23. Furumaya C, Martinez-Sanz P, Bouti P, Kuijpers TW, Matling KL. Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance. Front Immunol. 2020;11:2100.
25. Tazzym S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour angiogenesis. J Exp Pathol. 2009;90(3):207–15.

26. Shen M, Hu P, Donskov F, Wang G, Liu Q, Du J. Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PLoS ONE. 2014;9(6):e98259.

27. Shannon-Lowe C, Richardson AB, Bell AI. Epstein-Barr virus-associated lympho- mas. Philos Trans R Soc Lond B Biol Sci. 2017;372(1732).

28. Collins PJ, Fox CR, George LR, Ryan G, De Santis C, et al. Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. Blood. 2021;137(2):203–15.

29. Cai TT, Ye SB, Liu YN, He J, Chen QY, Mai HQ, et al. LMP1-mediated glycolysis induces myeloid-suppressor cell expansion in nasopharyngeal carcinoma. PLoS Pathog. 2017;13(7):e1006503.

30. Katahira Y, Higuchi H, Matsushita H, Yahata T, Yamamoto Y, Kikue R, et al. Increased Granulopoiesis in the Bone Marrow Following Epstein-Barr Virus Infection. Sci Rep. 2019;9(1):13445.

31. Li X, Li JL, Jiang N, Chen J, Liang ZM, Zhao ZL, et al. Accumulation of LOX-1(+) PDMS-DCs in nasopharyngeal carcinoma survivors with chronic hepatitis B might permit immune tolerance to Epstein-barr virus and relate to tumor recurrence. Aging. 2020;12(1):437–49.

32. Song Y, Li RJ, Zheng K, Jin Y, Zeng T. Epstein-Barr virus-encoded miR-BART11 promotes tumor-associated macrophage-induced epithelial-mesenchymal transition via targeting FOXP1 in gastric cancer. Virulence. 2020;5486–16.

33. Zhang B, Miao T, Shen X, Bao L, Zhang C, Yan C, et al. EB virus-induced ATR activation accelerates nasopharyngeal cancer growth via M2-type macrophages polarization. Cell Death Dis. 2020;11(9):742.

34. Ooft ML, van Ipenburg JA, Sanders ME, Kranendonk M, Hofland I, de Bree R, et al. Tumor-associated neutrophils and neutrophil-derived proteins in nasopharyngeal carcinoma: a tissue microarray analysis. Biomed Res Int. 2020;2020:6527192.

35. Shimakage M, Sakamoto H. Macrophage involvement in Epstein-Barr Virus-positive tumors. Exp Ther Med. 2010;1(2):285–91.

36. Kamper P, Bendix K, Hamilton-Dutoit S, Honoré B, Nyengaard JR, d’Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr Virus status in classical Hodgkin’s lymphoma. Haematologica. 2011;96(2):269–76.

37. Sato A, Yamakawa N, Okuyama K, Kotani A, Nakamura N, Ando K. The Critical Interaction Between Epstein-Barr Virus (EBV) Positive Cells and Tumor Associated Macrophages (TAMs). Blood. 2014;124(21):2989.

38. Xie Y. Hepatitis B Virus-Associated. Hepatocellular Carcinoma. Adv Exp Med Biol. 2017;1018:11–21.

39. Li T, Zhang X, Lv Z, Gao L, Yan H. Increased Expression of Myeloid-Derived Suppressor Cells in Patients with HBV-Related Hepatocellular Carcinoma. Biomed Res Int. 2020;2020:627192.

40. Pal S, Nandi M, Dey D, Chakraborty BC, Shil A, Ghosh S, et al. Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy. Aliment Pharmacol Ther. 2019;49(10):1346–59.

41. Zeng Y, Li Y, Xu Z, Gan W, Lu L, Huang X, et al. Myeloid-suppressor cells expansion is closely associated with disease severity and progression in HBV-related acute-on-chronic liver failure. J Med Virol. 2019;91(8):1510–8.

42. Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2010;11(4):382–9.

43. Yang P, Markowitz GJ, Wang XF. The hepatitis B virus-associated tumor micro-environment in hepatocellular carcinoma. Natl Sci Rev. 2014;1(3):396–412.

44. Bilyy MT, Cheng L, Zhang Z, Luan Y, Li F, Chi L, et al. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. PLoS Pathog. 2014;10(2):e1004092.

45. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu P, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206(6):1327–37.

46. Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 2012;56(4):1342–51.

47. Tong HY, Toan NL, Song LH, Bock CT, Kiensner PG, Velavan TP. Hepatitis B virus-induced hepatocellular carcinoma: functional roles of MICA variants. J Viral Hepat. 2013;20(10):687–98.

48. Ju Y, Hou N, Meng J, Wang X, Zhang X, Zhao D, et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol. 2010;52(3):322–9.

49. Peppa D, Micco L, Javid A, Kennedy PT, Schuech A, Dunn C, et al. Blockade of Immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog. 2010;6(12):e1001227.

50. Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res. 2017;27(1):59–73.

51. Zhai N, Li H, Song H, Yang Y, Cui A, Li T, et al. Hepatitis C Virus Induces MDSCs-Like Monocytes through TLR2/P38AKT/STAT3 Signaling. PLoS ONE. 2017;12(1):e0170516.

52. Tacke RS, Lee HC, Goh C, Courtney J, Poljak SJ, Rosen HR, et al. Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. Hepatology. 2012;55(2):343–53.

53. Goh CC, Roggenkom MM, Lee HC, Golden-Mason L, Rosen HR, Hahn YS. Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Suppress NK Cell IFN-y Production by Altering Cellular Metabolism via Arginase-1. J Immunol. 2015;194(12):7103–13.

54. Ren JP, Zhao J, Dai J, Griffin JW, Wang L, Wu YX, et al. Hepatitis C virus-induced myeloid-derived suppressor cells regulate T-cell differentiation and function via the signal transducer and activator of transcription 3 pathway. Immunol. 2014;168(4):377–86.

55. Wang M, Ping Y, Li Z, Li J, Zhang Z, Yue D, et al. Polarization of granulocytic myeloid-derived suppressor cells by hepatitis C core protein is mediated via IL-10/STAT3 signalling. J Viral Hepat. 2019;26(2):246–57.

56. Thakuri BKC, Zhang J, Zhao J, Nguyen LN, Nguyen LNT, Khanal S, et al. LncRNA HOTAIRM1 promotes MDSC expansion and suppressive functions through the HOXA1-miR124 axis during HCV infection. Sci Rep. 2020;10(1):22033.

57. Wang L, Gao D, Wang L, Zhao J, Nguyen LN, Dang X, et al. HCV-associated exosomes promote myeloid-derived suppressor cell expansion via inhibiting miR-124 to regulate T follicular cell differentiation and function. Cell Discov. 2018;4:51.

58. Thakuri BKC, Zhang J, Zhao J, Nguyen LN, Nguyen LNT, Schank M, et al. HCV-Associated Exosomes Upregulate RUNXOR and RUNX1 Expressions to Promote MDSC Expansion and Suppressive Functions through STAT3-miR124 Axis. Cells. 2020;9(12).

59. Mesri EA, Cesarman E, Boshoff C. Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010;10(10):707–19.

60. Balon G, Akar G, Cesarman E. Systemic expression of Kaposi sarcoma herpesvirus (KSHV) VHH in endothelial cells leads to a profound proinflammatory phenotype and myeloid lineage remodeling in vivo. PLoS Pathog. 2015;11(11):e1005481.

61. Campbell DM, Rappoccio G, Jenkins FJ, Rinaldo CR. Dendritic cells: key players in human herpesvirus 8 infection and pathogenesis. Front Microbiol. 2014;5:452.

62. Jenkins FJ, Minas TZ, Wang W, Dorsey TH, Ambos S. Human herpesvirus 8 infection is associated with prostate cancer among FNL4-6G carriers. Prostate Cancer and Prostatic Diseases. 2022.

63. Chavoshpour-Mamaghani S, Shoja Z, Mollaei-Kandelous Y, Sharifian K, Jalili B. Interaction Between Epstein-Barr Virus Positive B-Cells and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Polymorphic Nasopharyngeal Cancer and Prostatic Diseases. 2022.
70. Qian B-Z, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222–5.

71. Ren G, Zhao X, Wang Y, Zhang X, Chen X, Xu C, et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell. 2012;11(6):812–24.

72. Chun E, Lavrentiev S, Michaud M, Gallini CA, Kim J, Soucy G, et al. CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function. Cell Rep. 2015;12(2):244–57.

73. Fridlender ZG, Bachli G, Kapoor V, Cheng G, Sun J, Singhal S, et al. CCL2 blockade augments cancer immunotherapy. Cancer Res. 2010;70(1):109–18.

74. Bonapace L, Coissieux MM, Wijckoff J, Mertz KD, Varga Z, Junt T, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 2014;551(7680):130–3.

75. Pathria P, Louis TL, Varner JA. Targeting Tumor-Associated Macrophages in Cancer. Trends Immunol. 2019;40(4):310–27.

76. Kumar V, Giacomantonio MA, Gujar S. Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy. Viruses. 2021;13(46).

77. Hughes RA, Roodman GD, Muthana M, Kekki-Kouglou J, Olson OC, et al. Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Res. 2015;75(17):3479–91.

78. Scala S. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis–Untapped Potential in the Tumor Microenvironment. Clin Cancer Res. 2012;18(19):4278–85.

79. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927–31.

80. Zheng X, Turkowski K, Mora J, Brüne B, Seeger W, Weigert A, et al. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget. 2017;8(32):48436–52.

81. Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonate therapy. Nat Rev Cancer. 2015;14(11):731–41.

82. Jha AK, Huang SC, Sergushichev A, Lampropoulou V, Ivanova Y, Loginicheva S, O'Neill Luke AJ. A Broken Krebs Cycle in Macrophages. Immunity. 2015;42(3):393–4.

83. Zheng X, Su X, Liu R, Pan Y, Fang J, Cao L, et al. HDAC inhibition potentiates anti-angiogenic macrophage function and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057–69.

84. Magkouta SF, Vatsi PC, Pappas AG, Ilipoulos M, Kosti CN, Panagia N, et al. CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PD-L1 Immunotherapy. Cancers (Basel). 2021;13(11).

85. Brachan DC, Ruffell B, Che Y, Zhang G, Wang L, Fang Y, et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells. Oncoimmunology. 2013;2(12):e26968.

86. Holmgard RB, Zaminar D, Lesokhin A, Mergoht H, Wolchok JD. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxoygane-expressing tumors. ElBioMedicine. 2016;6:50–8.

87. Kumar V, Donthreddy L, Marvel D, Condamine T, Wang F, Lavilla-Antonio S, et al. Cancer-Associated Fibroblasts Neutralize the Anti-Tumor Effect of CSF1 Receptor Blockade by Inducing PNI-MDSC, Infiltration of Tumors. Cancer Cell. 2017;32(5):654–66.e5.

88. Hoxie S, Ooi CH, Wolter C, Sade H, Bissinger S, Schmittnekael M, et al. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. J Exp Med. 2018;215(3):859–76.

89. Wiehagen KR, Gigia NM, Yamada DH, Smith AA, Chan SR, Grewal IS, et al. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity. Cancer Immunol Res. 2017;5(12):1109–21.

90. Beatty GL, Choeun ER, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612–6.

91. Lau SP, van Montfoort N, Kinderman P, Lukkes M, Klaase L, van Nimwegen LA, et al. Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages. Cell Death Dis. 2018;9(8):678.

92. Liu J, Kanesa MMA, Ma J, Li M, Sheikh RM, Patel K, et al. P38δ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response. Proceedings of the National Academy of Sciences. 2021;118(16):e2009290118.

93. Joshi S, Singh AR, Zulic D, Murden DL. A macrophage-dominated R3Kδ isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis. Mol Cancer Res. 2014;12(10):1520–31.

94. Joshi S, Liu XK, Zulic D, Singh AR, Skola D, Glass CK, et al. Macrophage Syk-P38δ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemoxy Relieves Tumor Immunosuppression. Cancer Res. 2019;80(3):755–64.

95. Ochioni AC, Imbrosio Filho R, Estaves ME, Leandro JX, De Nascimento Junior FX, et al. Clotrimazole presents anticancer properties against a mouse melanoma model acting as a P38δ inhibitor and inducing polarization of tumor-associated macrophages. Biochem Biophys Acta Mol Basis Dis. 2021;1867(12):166263.

96. Yang Y, Mu R, Wang Z, Xie M, Zhang J, Dong L, et al. A toll-like receptor agonist mimicking microbial signal to generate tumor-suppressive macrophages. Nat Commun. 2019;10(1):2722.

97. Stoyllin CB, Aurluckska SP, Cuccurese MF, Garris CS, Li R, Ahmed MS, et al. TLIR/78-agonist-loaded nanoparticles promote the polarization of tumor-associated macrophages to enhance cancer immunotherapy. Nat Biomedical Eng. 2018;2(8):578–88.

98. Vishwarya A, Khan N, Agnihotri T, Negi S, Das DK, Agdas M, et al. TLIR-3 Stimulation Skews M2 Macrophages to M1 Through IFN-αβ Signaling and Restricts Tumor Progression. Front Immunol. 2018;9:1650.

99. Wang J, Shirota Y, Bayd D, Shirota H, Tross D, Guilly JL, et al. Effect of TLIR agonists on the differentiation and function of human monocyte myeloid-derived suppressor cells. J Immunol. 2015;194(9):4215–21.

100. Zhu Y, Knollhoff BL, Meyer MA, Nyvenning TM, West BL, Luo J, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Manji GA, Van Tine BA, Lee SM, Raufi AG, Pellicciotta I, Hirbe AC, et al. A Phase 1b/2 study of ARRY-382, an oral inhibitor of colony stimulating factor 1 receptor (CSF1R), in combination with pembrolizumab (Pembro) for patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. Invest New Drugs. 2021;39(4):1057–71.

Vonderheide RH. CD40 Agonist Antibodies in Cancer Immunotherapy. Annu Rev Med. 2020;71:147–58.

Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, et al. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Cancer Res. 2021;81(17):5457–64.

O’Hasa MH, O’Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, et al. CD40 agonistic monomeric antibody APX005M (sotaligalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021;22(1):119–31.

Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Huttner NA, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monomeric antibody. J Clin Oncol. 2007;25(7):876–83.

Cen X, Zhu G, Yang J, Yang J, Guo J, Jin J, et al. TR1/2 Specific Small-Molecule Agonist Suppresses Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes. Adv Sci (Weinh). 2019;6(18):18002042.

Megias J, Martinez A, San-Miguel T, Gil-Benso R, Munoz-Hidalgo L, Albert-Belver D, et al. Pam3CSK4, a TLR2 ligand, induces differentiation of glioblastoma stem cells and confers susceptibility to temozolomide. Invest New Drugs. 2020;38(2):299–310.

Long EM, Millen B, Rubes P, Robbins SM. Lipoteichoic acid induces unique inflammatory responses when compared to other toll-like receptor 2 ligands. PLoS ONE. 2009;4(5):e5601.

Sultan H, Wu J, Feisenkova VI, Fan AE, Addis D, Salazar AM, et al. Pol-yIC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration. J Immunother Cancer. 2020;8(2).

Gao H-X, Bhattacharya S, Matheny CJ, Yanamanda N, Zhang S-Y, Emerich H, et al. Synergy of TLR7 agonist GSK1795019, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecules OX40 in cancer immunotherapy. J Clin Oncol. 2018;36(15_suppl):12055-.

Nilsen NJ, Deininger S, Nonstad U, Skjeldal F, Husebye H, Rodionov D, et al. Cellular trafficking of lipoteichoic acid and Toll-like receptor 2 in relation to signaling: role of CD14 and CD36. J Leukoc Biol. 2008;84(1):280–91.

Diab A, Marcondes M, Kotzan B, Tagliaferri MA, Hoch U, Li Y, et al. Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 (TLR7/8 agonist) plus NKTR-214 [CD122-based agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial). J Clin Oncol. 2019;37(8_suppl):26.

Chi H, Liu C, Zhao FS, Zhang L, Ng TB, Jin G, et al. Anti-tumor Activity of Toll-Like Receptor 7 Agonists. Front Pharmacol. 2017;8:304.

Zanier DL, Spirig SJ, Brockwell NK, Owen KL, Zakhour JM, Robinson T, et al. Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer. Clin Transl Immunol. 2020;9(9):e1177.

Wang D, Jiang Y, Zhu F, Mao X, Agraval S. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy. Int J Oncol. 2018;53(3):1193–203.

Sabree SA, Voigt AP, Blackwell SE, Vishvikarana A, Chimienti MS, Salem AK, et al. Direct and indirect immune effects of CPM-001, a virus-like particle containing a TLR9 agonist. J Immunother Cancer. 2021;9(6).

Wang S, Campos J, Gallotta M, Gong M, Cram C, Naik E, et al. Intratumoral injection of a CpG oligonucleotide reverses resistance to PD-1 blockade by expanding multifunctional CD8 + T cells. Proc Natl Acad Sci U S A. 2016;113(46):E7240-e9.
157. Mathias MD, Sockolosky JT, Chang AY, Ten KS, Liu C, Garcia KC, et al. CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes. Leukemia. 2017;31(10):2254–7.

158. Petrova PS, Viller NN, Wong M, Pang X, Lin GH, Dodge K, et al. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin Cancer Res. 2017;23(4):1068–79.

159. Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. J Clin Oncol. 2019;37(12):946–53.

160. La Fleur L, Boura VF, Alexeyenko A, Berglund A, Pontén V, Mattsson JSM, et al. Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer. Int J Cancer. 2018;143(7):1741–52.

161. Min AKT, Mimura K, Nakajima S, Okayama H, Saito K, Sakamoto W, et al. Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer. Cancer Immunol Immunother. 2021;70(2):289–98.

162. Zhang Q, Wang J, Yadav DK, Bai X, Liang T. Glucose Metabolism: The Metabolic Signature of Tumor Associated Macrophage. Front Immunol. 2021;12:702580.

163. Lee C, Jeong H, Bae Y, Shin K, Kang S, Kim H, et al. Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide. J Immunother Cancer. 2019;7(1):147.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.